PPARγ Variant Influences Angiographic Outcome and 10-Year Cardiovascular Risk in Male Symptomatic Coronary Artery Disease Patients
Response to Regieli et al.
- Jochen G. Schneider, MD1,
- Stephan Schiekofer, MD2,
- Maximilian von Eynatten, MD3 and
- Klaus A. Dugi, MD4
- 1Department of Medicine, Washington University in St. Louis, St. Louis, Missouri;
- 2Department of Medicine, Saarland University School of Medicine, Homburg/Saar, Germany;
- 3Department of Nephrology, University of Munich, Munich, Germany;
- 4Department of Medicine I (Endocrinology and Metabolism), Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany.
- Corresponding author: Jochen G. Schneider, js{at}mailbox-js.de.
Peroxisome proliferator–activated receptor (PPAR)γ is a nuclear transcription factor modulating the transcriptional regulation of many genes involved in metabolism and energyhomeostasis. Although several studies have addressed the metabolic profile of carriers of a common polymorphism in PPARγ2 (Pro12Ala), there is no clear consensuson whetherthe metabolic benefits thataccompany12Ala carriers would translate into a protection from cardiovascular disorders. The study of a potential association between the Pro12Ala polymorphism and angiographic and cardiovascular outcome in the REGRESS (Regression Growth Evaluation Statin Study) cohort by Regieli et al. (1) has concluded that carriers of the 12Ala allele in PPARγ …
